<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02670408</url>
  </required_header>
  <id_info>
    <org_study_id>ATAGC 002</org_study_id>
    <nct_id>NCT02670408</nct_id>
  </id_info>
  <brief_title>Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation</brief_title>
  <official_title>Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation, a Multicenter Study (INTERHEART)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Demonstrate the impact of the Molecular Microscope Diagnostic System as the standard of care
      for heart transplant patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard for biopsy-based diagnoses of rejection of heart transplants is the
      ISHLT classification from 2004, which represents a widely-used international consensus, based
      on morphological criteria of the cellular infiltrate within the myocardial specimen system
      with certainties and some arbitrary and blurred parameters. Recent data-driven approaches
      using molecular and conventional technologies indicate that this system produces incorrect
      diagnoses with potential harm to patients due to inappropriate treatment. To address this
      unmet need and improve diagnostics in the area of organ transplantation, the Alberta
      Transplant Applied Genomics Centre (ATAGC, University of Alberta) has developed a new
      diagnostic system - the Molecular Microscope™ Diagnostic System (MMDx) that interprets
      biopsies in terms of their molecular phenotype, and combines the molecular and
      histopathological features of transplant biopsies, plus clinical and laboratory parameters,
      to create the first Integrated Diagnostic System. The MMDx developed first in kidney
      transplant biopsies because phenotypes are well established, will now be adapted to heart
      transplant endomyocardial biopsies (EMBs). The present study will develop a Reference Set of
      EMB, adapt the MMDx™ system to assess and report EMBs; and validate and refine this system in
      900 unselected prospectively collected for clinical indications and a standard of care EMBs
      from North American and European Centers. In addition to demonstrating the real-time
      feasibility and potential value of this System in patient care, the study will develop and
      optimize a transparent and user-friendly reporting format to communicate this information to
      clinicians and obtain detailed feedback to improve its utility. We refine now our MMDx system
      using a new type of analysis (see primary outcome) and the resulting MMDx report.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assign molecular scores (probability) of T cell mediated rejection, antibody mediated rejection in heart transplant biopsies, in a reference set of 200 biopsies</measure>
    <time_frame>2 years</time_frame>
    <description>Create a molecular classifier that predicts antibody mediated and T cell mediated rejection, based on the archetypal analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assign in real time (three working days upon biopsy receipt) molecular scores (probability) of T cell mediated rejection and antibody mediated rejection.</measure>
    <time_frame>1 year</time_frame>
    <description>The molecular phenotype of a newly acquired sample predicts the histologic and clinical features of this sample when compared to the reference set.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">900</enrollment>
  <condition>Cardiac Transplant Disorder</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Endomyocardial biopsy</intervention_name>
    <description>One of several endomyocardial biopsy bites taken as the standard of care. We are asking now for two endomyocardial biopsy bites, to determine tissue sampling variability.</description>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biopsy extract containing RNA
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        This study aims to recruit 1200 biopsies from heart transplant patients for clinical
        indications and the standard of care biopsies.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy for clinical indications

        Exclusion Criteria:

          -  no consent

          -  pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip F Halloran, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alberta</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Konrad S Famulski, PhD</last_name>
    <phone>1 7804921725</phone>
    <email>konrad@ualberta.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Polakowski, PhD</last_name>
    <phone>1780 492 5091</phone>
    <email>polakows@ualberta.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cedars-Sinai Heart Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Starks, MBA</last_name>
      <phone>310-248-7141</phone>
      <email>email:jon.kobashigawa@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Jon Kobashigawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Centre</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>CA 90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eugene DePasquale, MD</last_name>
      <email>EDepasquale@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Martin Cadeiras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Medicine, University of Utah Health</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>UT 84132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josef Stehlik, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Josef Stehlik, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University, Division of Cardiology</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>VA 23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura H Johnson, BSN RN</last_name>
      <phone>804-682-2452</phone>
    </contact>
    <investigator>
      <last_name>Keyur B Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiac Transplantation Laboratory, The Victor Chang Cardiac Research Institute</name>
      <address>
        <city>Darlinghurst</city>
        <zip>NSW 2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Herrera, MD</last_name>
      <phone>61-02-8382-3025</phone>
      <email>peter.macdonal@svha.org.au</email>
    </contact>
    <investigator>
      <last_name>Peter MacDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiac Surgery, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arezu Aliabadi, MD</last_name>
      <phone>43-1-40400-5643</phone>
      <email>arezu.aliabadi@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Andreas Zuckerman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Transplant Applied Genomics Center, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konrad Famulski, PhD</last_name>
      <phone>7804921725</phone>
      <email>konrad@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Philip F Halloran, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Division of Cardiology, University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 2R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Kim, MD</last_name>
      <phone>1 780-407-7206</phone>
      <email>dk@ualberta.ca</email>
    </contact>
    <investigator>
      <last_name>Daniel Kim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie-Dialyse Adultes , Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Heart Failure and Heart Transplant Unit, University of Bologna</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Borgese</last_name>
      <phone>39-380-3577261</phone>
      <email>Laura.Botgese@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luciano Potena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advanced Heart Failure Transplant Unit</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zulaika Grille Cancela</last_name>
      <phone>34-981-176-540</phone>
      <phone_ext>29 10 19</phone_ext>
      <email>Zulaika.grille.cancela@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Maria G Crespo-Leiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Italy</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Loupy A, Duong Van Huyen JP, Hidalgo L, Reeve J, Racapé M, Aubert O, Venner JM, Falmuski K, Bories MC, Beuscart T, Guillemain R, François A, Pattier S, Toquet C, Gay A, Rouvier P, Varnous S, Leprince P, Empana JP, Lefaucheur C, Bruneval P, Jouven X, Halloran PF. Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection. Circulation. 2017 Mar 7;135(10):917-935. doi: 10.1161/CIRCULATIONAHA.116.022907. Epub 2017 Feb 1.</citation>
    <PMID>28148598</PMID>
  </results_reference>
  <results_reference>
    <citation>Halloran PF, Potena L, Van Huyen JD, Bruneval P, Leone O, Kim DH, Jouven X, Reeve J, Loupy A. Building a tissue-based molecular diagnostic system in heart transplant rejection: The heart Molecular Microscope Diagnostic (MMDx) System. J Heart Lung Transplant. 2017 Nov;36(11):1192-1200. doi: 10.1016/j.healun.2017.05.029. Epub 2017 May 29.</citation>
    <PMID>28662985</PMID>
  </results_reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>January 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2016</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Alberta</investigator_affiliation>
    <investigator_full_name>Philip Halloran</investigator_full_name>
    <investigator_title>Distinguished Professor</investigator_title>
  </responsible_party>
  <keyword>Heart transplant</keyword>
  <keyword>global gene expression</keyword>
  <keyword>molecular diagnostics</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

